% | $
Quotes you view appear here for quick access.

InterMune, AŞ Message Board

  • nhanduyvo nhanduyvo Jan 9, 2014 7:54 AM Flag

    Great News on Revenue and Especially on the ASCEND Trial

    Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "2013 was a year of strong execution and growing momentum in every part of our business. Revenue from our Esbriet product, marketed in certain European countries and Canada for the treatment of patients with idiopathic pulmonary fibrosis, or IPF, grew by 168 percent in 2013 to approximately $70.2 million, and we expect Esbriet revenue growth to continue in 2014 by 65-90 percent to $115-$135 million. We are proud to have reported four consecutive quarters of revenue growth during 2013 and nine consecutive quarters of growth since Esbriet was first launched. Our European operations are performing well and we expect cash flows from our European sales to fully support our European operations sometime in the latter half of 2014.

    "Today, we announced that we expect to communicate top-line results from the ASCEND study early in the second quarter of 2014, and to present the study results at the American Thoracic Society (ATS) conference in May 2014," Mr. Welch added. "As we closed out 2013, we announced our progress and planned investments in our growing R&D pipeline that build on our commercial momentum with Esbriet, leverage our expertise in IPF and fibrosis and move us toward realizing our strategic vision of becoming a leader in specialty fibrotic diseases."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Study conduct in ASCEND remains excellent with a level of patient retention in the study that exceeds 90 percent. More than 95 percent of eligible patients (those patients who remain on blinded pirfenidone or placebo therapy) who have completed the ASCEND study have decided to enter the open-label RECAP extension study. RECAP is a study in which all patients receive pirfenidone. RECAP also includes patients rolled over from the company's prior CAPACITY program which completed in late 2008 and enrolled 779 patients in two Phase 3 studies. RECAP provides valuable long-term safety data that further expands the already large safety database for pirfenidone in patients with IPF.

      • 1 Reply to nhanduyvo
      • A small "Told you so:" there WAS some slop in the timing of last patient treatment relative to the Clinicaltrials estimate. Maybe 2 weeks early. I'm guessing on a little further slop, possibly enough to move the ASCEND topline just into the first quarter (difficulty of analysis drops sharply at high patient retention rates).

        I'd like to point out that the very existence of a RECAP study population, mostly diagnosed by 2006, supports the case for Esbriet.